uniQure (NASDAQ:QURE) Director Jack Kaye Sells 2,645 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 2,645 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $30.01, for a total value of $79,376.45. Following the completion of the sale, the director directly owned 20,439 shares in the company, valued at $613,374.39. This trade represents a 11.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Down 5.5%

uniQure stock opened at $26.45 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -7.60 and a beta of 0.98. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The stock’s fifty day moving average is $21.39 and its two-hundred day moving average is $21.86.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Analysts predict that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on QURE. Wolfe Research began coverage on uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating on the stock. Cantor Fitzgerald restated a “neutral” rating and issued a $9.00 price objective (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Barclays reduced their price objective on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Monday, March 23rd. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, The Goldman Sachs Group upped their price objective on uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a research report on Monday, April 20th. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $42.83.

Institutional Trading of uniQure

Hedge funds have recently added to or reduced their stakes in the business. Torren Management LLC acquired a new stake in uniQure in the 4th quarter worth about $28,000. Jones Financial Companies Lllp boosted its stake in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the last quarter. IFP Advisors Inc acquired a new stake in uniQure in the 4th quarter worth about $48,000. Smartleaf Asset Management LLC acquired a new stake in uniQure in the 4th quarter worth about $48,000. Finally, CIBC Private Wealth Group LLC purchased a new position in shares of uniQure in the 3rd quarter worth about $50,000. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.